Table 1 Current Value Frameworks
Framework | Factors considered | Purpose | Costs measured? | Perspective |
|---|---|---|---|---|
ASCO Framework | Net Health Benefit: Clinical Benefit (OS > PFS > RR), Toxicity, Extended Survival | Comparison of two regimens that have been reported in a randomized clinical trial | No | Patient |
ESMO-MCBS | Magnitude of Clinical Benefit: Prognosis of Condition, Clinical Benefit (OS, PFS), Long-term Survival (HR, RR), Quality of Life, Toxicity | Comparison of magnitude of benefit of regimens with reported comparative research outcomes | No | Societal |
NCCN Evidence Blocks | Efficacy, Safety, Quality of Evidence, Consistency of Evidence, Affordability | Visual representation of key factors that provide information about the value of the recommendations within the guidelines | Yes | Patient |
MSKCC Drug Abacus | Efficacy, Cost Toxicity, Treatment Novelty, Costs of Development, Rarity of Disease, Population Burden of Condition | Intended to provide information regarding the proper pricing of new drugs in the market | Yes | Societal |
ICER Value Framework | Incremental Cost - Effectiveness Ratio: \( \frac{\mathrm{Cos}{\mathrm{t}}_{\mathrm{new}}-\mathrm{Cos}{\mathrm{t}}_{\mathrm{s}\mathrm{tandard}}}{\mathrm{Effectivenes}{\mathrm{s}}_{\mathrm{new}}-\mathrm{Effectivenes}{\mathrm{s}}_{\mathrm{s}\mathrm{tandard}}} \) | Comparison of two treatments based on efficacy and cost | Yes | Societal |